Abstract | PURPOSE:
Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin's preclinical antitumor efficacy in a variety of sensitive and resistant human tumor cell lines and in a prostate cancer xenograft model and to evaluate the effect of satraplatin on PSA expression and/or secretion in a prostate cancer cell line. METHODS:
Satraplatin and its primary metabolite JM-118 were preclinically tested for their cytotoxic activity in a range of cancer cells including: human prostate, those forming the NCI drug screening panel, and those resistant to anti- cancer drugs. Also, the antiproliferative efficacy of satraplatin was tested in vivo in a human prostate cancer model. The effect of satraplatin and JM-118 on PSA transcription was measured by quantitative real time PCR. RESULTS: CONCLUSIONS:
|
Authors | Katja Wosikowski, Lou Lamphere, Gerhard Unteregger, Volker Jung, Faith Kaplan, Jimmy P Xu, Benno Rattel, Maureen Caligiuri |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 60
Issue 4
Pg. 589-600
(Sep 2007)
ISSN: 0344-5704 [Print] Germany |
PMID | 17541592
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Organoplatinum Compounds
- amminedichloro(cyclohexylamine)platinum(II)
- satraplatin
- Prostate-Specific Antigen
|
Topics |
- Administration, Oral
- Animals
- Antineoplastic Agents
(pharmacology)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Drug Resistance, Neoplasm
(drug effects)
- Humans
- Male
- Mice
- Mice, Nude
- Organoplatinum Compounds
(pharmacology)
- Prostate-Specific Antigen
(metabolism)
- Prostatic Neoplasms
(drug therapy)
- Xenograft Model Antitumor Assays
|